235 related articles for article (PubMed ID: 8102646)
1. Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies.
Sorensen SM; Kehne JH; Fadayel GM; Humphreys TM; Ketteler HJ; Sullivan CK; Taylor VL; Schmidt CJ
J Pharmacol Exp Ther; 1993 Aug; 266(2):684-91. PubMed ID: 8102646
[TBL] [Abstract][Full Text] [Related]
2. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.
Kehne JH; Baron BM; Carr AA; Chaney SF; Elands J; Feldman DJ; Frank RA; van Giersbergen PL; McCloskey TC; Johnson MP; McCarty DR; Poirot M; Senyah Y; Siegel BW; Widmaier C
J Pharmacol Exp Ther; 1996 May; 277(2):968-81. PubMed ID: 8627580
[TBL] [Abstract][Full Text] [Related]
3. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
[TBL] [Abstract][Full Text] [Related]
4. Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors.
Maurel-Remy S; Bervoets K; Millan MJ
Eur J Pharmacol; 1995 Jul; 280(2):R9-11. PubMed ID: 7589172
[TBL] [Abstract][Full Text] [Related]
5. Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats.
Kehne JH; Ketteler HJ; McCloskey TC; Sullivan CK; Dudley MW; Schmidt CJ
Neuropsychopharmacology; 1996 Aug; 15(2):116-24. PubMed ID: 8840347
[TBL] [Abstract][Full Text] [Related]
6. The role of 5-HT(2A) receptor antagonism in amphetamine-induced inhibition of A10 dopamine neurons in vitro.
Olijslagers JE; Perlstein B; Werkman TR; McCreary AC; Siarey R; Kruse CG; Wadman WJ
Eur J Pharmacol; 2005 Sep; 520(1-3):77-85. PubMed ID: 16154561
[TBL] [Abstract][Full Text] [Related]
7. Electrophysiological effects of BMY 14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: acute and chronic studies.
Wachtel SR; White FJ
J Pharmacol Exp Ther; 1988 Jan; 244(1):410-6. PubMed ID: 2891845
[TBL] [Abstract][Full Text] [Related]
8. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
[TBL] [Abstract][Full Text] [Related]
9. Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats.
Wadenberg MG; Browning JL; Young KA; Hicks PB
Pharmacol Biochem Behav; 2001 Mar; 68(3):363-70. PubMed ID: 11325387
[TBL] [Abstract][Full Text] [Related]
10. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.
Marquis KL; Sabb AL; Logue SF; Brennan JA; Piesla MJ; Comery TA; Grauer SM; Ashby CR; Nguyen HQ; Dawson LA; Barrett JE; Stack G; Meltzer HY; Harrison BL; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2007 Jan; 320(1):486-96. PubMed ID: 17038512
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
[TBL] [Abstract][Full Text] [Related]
12. Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2A antagonist.
Moser PC; Moran PM; Frank RA; Kehne JH
Behav Brain Res; 1996; 73(1-2):163-7. PubMed ID: 8788496
[TBL] [Abstract][Full Text] [Related]
13. CI-943, a potential antipsychotic agent. III. Evaluation of effects on dopamine neuronal activity.
Meltzer LT; Christoffersen CL; Heffner TG; Freeman AS; Chiodo LA
J Pharmacol Exp Ther; 1989 Oct; 251(1):123-30. PubMed ID: 2571714
[TBL] [Abstract][Full Text] [Related]
14. Effects of ICI 169,369, a selective serotonin2 antagonist, in electrophysiological tests predictive of antipsychotic activity.
Goldstein JM; Litwin LC; Sutton EB; Malick JB
J Pharmacol Exp Ther; 1989 Jun; 249(3):673-80. PubMed ID: 2567348
[TBL] [Abstract][Full Text] [Related]
15. Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone.
Schreiber R; Brocco M; Millan MJ
Eur J Pharmacol; 1994 Oct; 264(1):99-102. PubMed ID: 7530204
[TBL] [Abstract][Full Text] [Related]
16. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
17. Seroquel: electrophysiological profile of a potential atypical antipsychotic.
Goldstein JM; Litwin LC; Sutton EB; Malick JB
Psychopharmacology (Berl); 1993; 112(2-3):293-8. PubMed ID: 7871033
[TBL] [Abstract][Full Text] [Related]
18. 5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine.
Schmidt CJ; Fadayel GM; Sullivan CK; Taylor VL
Eur J Pharmacol; 1992 Nov; 223(1):65-74. PubMed ID: 1362159
[TBL] [Abstract][Full Text] [Related]
19. The orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: implications for antipsychotic therapy.
Rasmussen K; Hsu MA; Yang Y
Neuropsychopharmacology; 2007 Apr; 32(4):786-92. PubMed ID: 17063151
[TBL] [Abstract][Full Text] [Related]
20. Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal.
Broderick PA; Hope O; Okonji C; Rahni DN; Zhou Y
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):157-71. PubMed ID: 14687870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
